Literature DB >> 23347891

Characteristics of sequential targeting of brain glioma for transferrin-modified cisplatin liposome.

Qing Lv1, Li-Min Li, Min Han, Xin-Jiang Tang, Jin-Na Yao, Xiao-Ying Ying, Fan-Zhu Li, Jian-Qing Gao.   

Abstract

Methods on how to improve the sequential targeting of glioma subsequent to passing of drug through the blood-brain barrier (BBB) have been occasionally reported. However, the characteristics involved are poorly understood. In the present study, cisplatin (Cis) liposome (lipo) was modified with transferrin (Tf) to investigate the characteristics of potential sequential targeting to glioma. In bEnd3/C6 co-culture BBB models, higher transport efficiency across the BBB and cytotoxicity in basal C6 cells induced by Cis-lipo(Tf) than Cis-lipo and Cis-solution, suggest its sequential targeting effect. Interestingly, similar liposomal morphology as that of donor compartment was first demonstrated in the receptor solution of BBB models. Meanwhile, a greater acquisition in the lysosome of bEnd3, distributed sequentially into the nucleus of C6 cells were found for the Cis-lipo(Tf). Pre-incubation of chlorpromazine and Tf inhibited this process, indicating that a clathrin-dependent endocytosis is involved in the transport of Cis-lipo(Tf) across the BBB.
Copyright © 2013 Elsevier B.V. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23347891     DOI: 10.1016/j.ijpharm.2013.01.025

Source DB:  PubMed          Journal:  Int J Pharm        ISSN: 0378-5173            Impact factor:   5.875


  15 in total

Review 1.  Promising approaches to circumvent the blood-brain barrier: progress, pitfalls and clinical prospects in brain cancer.

Authors:  Iason T Papademetriou; Tyrone Porter
Journal:  Ther Deliv       Date:  2015-08-25

Review 2.  Emerging research and clinical development trends of liposome and lipid nanoparticle drug delivery systems.

Authors:  John C Kraft; Jennifer P Freeling; Ziyao Wang; Rodney J Y Ho
Journal:  J Pharm Sci       Date:  2013-11-25       Impact factor: 3.534

3.  Cytotoxicity of PEGylated liposomes co-loaded with novel pro-apoptotic drug NCL-240 and the MEK inhibitor cobimetinib against colon carcinoma in vitro.

Authors:  Shravan Kumar Sriraman; Vananelia Geraldo; Ed Luther; Alexei Degterev; Vladimir Torchilin
Journal:  J Control Release       Date:  2015-10-21       Impact factor: 9.776

Review 4.  Blood brain barrier: a challenge for effectual therapy of brain tumors.

Authors:  Arijit Bhowmik; Rajni Khan; Mrinal Kanti Ghosh
Journal:  Biomed Res Int       Date:  2015-03-19       Impact factor: 3.411

5.  Plasmid pORF-hTRAIL targeting to glioma using transferrin-modified polyamidoamine dendrimer.

Authors:  Song Gao; Jianfeng Li; Chen Jiang; Bo Hong; Bing Hao
Journal:  Drug Des Devel Ther       Date:  2015-12-17       Impact factor: 4.162

Review 6.  Barriers to drug delivery in solid tumors.

Authors:  Shravan Kumar Sriraman; Bhawani Aryasomayajula; Vladimir P Torchilin
Journal:  Tissue Barriers       Date:  2014-07-22

7.  Development of docetaxel nanocrystals surface modified with transferrin for tumor targeting.

Authors:  Jin-Seok Choi; Jeong-Sook Park
Journal:  Drug Des Devel Ther       Date:  2016-12-16       Impact factor: 4.162

8.  Transferrin-modified liposomes triggered with ultrasound to treat HeLa cells.

Authors:  Nour M AlSawaftah; Nahid S Awad; Vinod Paul; Paul S Kawak; Mohammad H Al-Sayah; Ghaleb A Husseini
Journal:  Sci Rep       Date:  2021-06-02       Impact factor: 4.379

9.  Rapid modification of antibodies on the surface of liposomes composed of high-affinity protein A-conjugated phospholipid for selective drug delivery.

Authors:  Susumu Hama; Mika Sakai; Shoko Itakura; Eiji Majima; Kentaro Kogure
Journal:  Biochem Biophys Rep       Date:  2021-07-02

10.  Non-viral liposome-mediated transfer of brain-derived neurotrophic factor across the blood-brain barrier.

Authors:  Ying Xing; Chun-Yan Wen; Song-Tao Li; Zong-Xin Xia
Journal:  Neural Regen Res       Date:  2016-04       Impact factor: 5.135

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.